Abstract: The RBD-mRNA-induced antibodies exerted moderate neutralization against authentic B.1.617.2 and B.1.1.529 variants, and pseudotyped B.1.351 and P.1 lineage variants containing K417N/T, E484K, and N501Y mutations, the B.1.617.2 lineage variant harboring L452R, T478K, and P681R mutations, and the B.1.1.529 lineage variant containing 38 mutations in the S protein.
COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants.
Abstract: ACE2 binding inhibition was reduced for ten out of eleven variants examined compared to wild-type, especially for those displaying the E484K mutation such as VOCs beta and gamma.
Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected patients.
Abstract: Moreover, introducing the 484 K mutation into RaTG13 resulted in increased neutralisation, in contrast to the same mutation in SARS-CoV-2 (E484K).
Abstract: This is despite E484K having a well-documented role in immune evasion in variants of concern (VOC) such as B.1.351 (Beta).
Convergent Evolution of Multiple Mutations Improves the Viral Fitness of SARS-CoV-2 Variants by Balancing Positive and Negative Selection.
Abstract: E484K escapes Class 2 antibodies; however, it has decreased receptor binding, stability, and expression.
Abstract: Triple mutant K417T/E484K/N501Y has increased receptor binding, escapes both Class 1 and Class 2 antibodies, and has similar stability and expression as that of the wild-type.
Abstract: We examined the physical mechanisms underlying the convergent evolution of three mutations K417T/E484K/N501Y by delineating the individual and collective effects of mutations on binding to angiotensin converting enzyme 2 receptor, immune escape from neutralizing antibodies, protein stability, and expression.
Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds.
Introduction: For instance, the E484K mutation in the RBD in several VOCs has been reported to cause up to a ten-fold reduction of neutralisation, while the more recent L452R mutation found in B.1.427/B.1.429, a VOC originally detected in California, USA, resulted in a 4 fold reduction.
Introduction: This new variant has the E484K mutation in the Spike protein that is believed to have a strong impact on antibody evasion.
Table: E484K
A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike.
Method: Pre-fusion spike protein ectodomain DNA constructs were designed containing the following mutations compared to the Wuhan variant (Wuhan Hu-1; GenBank: MN908947.3): deletion of H69, V70 and Y144, N501Y, A570D, D614G, P681H, T716I, S982A and D1118H in Alpha; L18F, D80A, D215G, L242H, R246I, K417N, E484K, N501Y, D614G and A701V in Beta;
SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines.
Introduction: And cilgavimab had lower activity against N501Y+D614G mutants, including B.1.429 (carrying L452R), B.1.617.2 (carrying L452R + T478K) and B.1.351 (carrying K417N + E484K + N501Y).
Introduction: E484 substitutions have been identified in a number of VOCs, including B.1.351 (E484K), P.1 (E484K), B.1.617.2 (E484K/E484Q) and B.1.1.529 (E484A) (https://covariants.org/variants/S.E484).
Introduction: Examples include the N501Y, S477N, PMID: 35279013
2022
Biomedicine & pharmacotherapy
Result: After treatment of the cells with the indicated concentration of GB-1, the number of 293 T cells with high binding to the RBD with K417T-E484K-N501Y mutation was decreased in both ACE2-positive cells and the top population in the 200-300 mug/mL GB-1 treatment group .
Result: After treatment of the cells with the indicated concentration of GB-1, the number of 293 T cells with low binding to the RBD with K417N-E484K-N501Y mutation was significantly increased in both ACE2-positive cells and the top popula
Result: After treatment of the cells with the indicated concentration of GB-1, the number of 293 T cells with low binding to the RBD with E484K mutation was significantly increased in both ACE2-positive cells and the top population .
Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections.
Introduction: The E484Q mutation site in B.1.617 is similar to mutations in variants B.1.351 and P.1(E484K), which is a key site that lead to immune escape.
Result: E484K-mediated immune escape has been reported by many groups; this comprises a key mutation in many VOCs and VOIs (e.g.
Result: Additionally, we compared the E484Q and E484K mutations.
Result: Furthermore, E484Q induced neutralization resistance to an extent comparable with the resistance induced by E484K.
Result: Notably, although E484Q and E484K both involve an identical mutation site, E484K allowed escape from the AM128 mAb, whereas
SARS_CoV_2 mutation literature information.
PMID: 
2022
Translational research
Browser Board
Co-occurred Entities
Filtrator
ViMRT